Grifols Stock Forecast, Price & News

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Grifols in the last year. There are currently 3 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Grifols stock.
View analyst ratings for Grifols or view top-rated stocks.

Wall Street analysts have given Grifols a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Grifols wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Grifols, S.A. (NASDAQ:GRFS) released its quarterly earnings data on Friday, February, 26th. The biotechnology company reported $0.29 earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of $0.38 by $0.09. The biotechnology company earned $1.56 billion during the quarter, compared to analyst estimates of $1.63 billion. Grifols had a net margin of 12.79% and a trailing twelve-month return on equity of 10.65%.
View Grifols' earnings history.

Grifols' stock was trading at $20.36 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, GRFS shares have decreased by 8.6% and is now trading at $18.60.
View which stocks have been most impacted by COVID-19.

Grifols announced a semi-annual dividend on Thursday, October 22nd. Shareholders of record on Monday, November 2nd will be given a dividend of $0.1445 per share on Monday, November 9th. This represents a yield of 1.6%. The ex-dividend date of this dividend is Friday, October 30th.
View Grifols' dividend history.

Grifols pays an annual dividend of $0.14 per share and currently has a dividend yield of 0.77%. The dividend payout ratio of Grifols is 11.97%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Grifols will have a dividend payout ratio of 9.27% next year. This indicates that Grifols will be able to sustain or increase its dividend.
View Grifols' dividend history.

Grifols shares split before market open on Monday, January 4th 2016. The 2-1 split was announced on Thursday, December 3rd 2015. The newly minted shares were payable to shareholders after the market closes on Thursday, December 31st 2015. An investor that had 100 shares of Grifols stock prior to the split would have 200 shares after the split.

205 employees have rated Grifols CEO Raimon Grifols and Victor Grifols Deu on Glassdoor.com. Raimon Grifols and Victor Grifols Deu has an approval rating of 68% among Grifols' employees.

Some companies that are related to Grifols include Alexion Pharmaceuticals (ALXN), BeiGene (BGNE), Astellas Pharma (ALPMY), Shiseido (SSDOY), Takeda Pharmaceutical (TKPYY), Royalty Pharma (RPRX), Genmab A/S (GMAB), Genmab A/S (GNMSF), MERCK Kommanditgesellschaft auf Aktien (MKGAF), CureVac (CVAC), Horizon Therapeutics Public (HZNP), Catalent (CTLT), UCB (UCBJF), Alnylam Pharmaceuticals (ALNY) and Zai Lab (ZLAB).
View all of GRFS's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Grifols investors own include Gilead Sciences (GILD), Pfizer (PFE), Teva Pharmaceutical Industries (TEVA), Abbott Laboratories (ABT), Alibaba Group (BABA), Johnson & Johnson (JNJ), NVIDIA (NVDA), AbbVie (ABBV), Bristol-Myers Squibb (BMY) and Nektar Therapeutics (NKTR).

Grifols trades on the NASDAQ under the ticker symbol "GRFS."

Grifols' stock is owned by many different retail and institutional investors. Top institutional shareholders include Cardinal Capital Management (0.01%), FDx Advisors Inc. (0.00%) and Reilly Financial Advisors LLC (0.00%).

GRFS stock was sold by a variety of institutional investors in the last quarter, including Reilly Financial Advisors LLC, and FDx Advisors Inc..

GRFS stock was bought by a variety of institutional investors in the last quarter, including Cardinal Capital Management.

Shares of GRFS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of GRFS stock can currently be purchased for approximately $18.60.

Grifols has a market capitalization of $12.79 billion and generates $5.71 billion in revenue each year. The biotechnology company earns $700.16 million in net income (profit) each year or $1.17 on an earnings per share basis.

Grifols employs 23,655 workers across the globe.

The following companies are subsidiares of Grifols: Aigües Minerals de Vilajuiga S.A., Araclon Biotech, Araclon Biotech S.L., Asociación I+D Progenika, Biomat S.A., Biomat USA Inc., Biotest Pharmaceutical Corporation, Biotest US Corporation, Chiquito Acquisition Corp., Diagnostic Grifols S.A., Goetech LLC (D/B/A Medkeeper), Gri-Cel S.A. , Grifols (H.K.) Limited, Grifols (Thailand) Ltd, Grifols Argentina S.A., Grifols Asia Pacific Pte Ltd, Grifols Australia Pty Ltd., Grifols Biologicals LLC., Grifols Brasil Lda., Grifols Canada Ltd., Grifols Chile S.A., Grifols Colombia Ltda, Grifols Deutschland GmbH, Grifols Diagnostics Equipment Taiwan Limited, Grifols Diagnostics Solutions Inc, Grifols Engineering S.A., Grifols France S.A.R.L., Grifols India Healthcare Private Ltd, Grifols Innovation and New Technologies Limited, Grifols International S.A., Grifols Italia S.p.A, Grifols Japan K.K., Grifols Malaysia Sdn Bhd, Grifols Movaco S.A., Grifols México S.A. de C.V., Grifols Nordic AB, Grifols Pharmaceutical Technology (Shanghai) Co. Ltd., Grifols Polska Sp.z.o.o., Grifols Portugal Productos Farmacéuticos e Hospitalares Lda., Grifols Shared Services North America Inc., Grifols Switzerland AG, Grifols Therapeutics LLC., Grifols UK Ltd., Grifols USA LLC., Grifols Viajes S.A., Grifols Worldwide Operations Limited, Grifols Worldwide Operations Spain S.A., Grifols Worldwide Operations USA Inc., Grifols s.r.o., Gripdan Invest S.L, Haema AG, Instituto Grifols S.A., Interstate Blood Bank Inc., Kiro Grifols S.L, Kiro Robotics, Laboratorios Grifols S.A., Logística Grifols S.A. de C.V., Medion Diagnostics GmbH, Medion Grifols Diagnostic AG, PBS Acquisition Corp., Progenika Biopharma, Progenika Biopharma S.A., Squadron Reinsurance Designated Activity Company, Talecris Biotherapeutics, Talecris Plasma Resources Inc., and VCN Bioscience S.L..

Grifols was founded in 1909.

The official website for Grifols is www.grifols.com.

Grifols is headquartered at 152 PARC DE NEGOCIS CAN SANT JOAN SANT CUGAT DEL VALL¿S, BARCELONA U3, 08174.

Grifols' mailing address is 152 PARC DE NEGOCIS CAN SANT JOAN SANT CUGAT DEL VALL¿S, BARCELONA U3, 08174. The biotechnology company can be reached via phone at (493) 571-2200 or via email at [email protected]